AR065583A1 - Compuestos macrociclicos y composicion farmaceutica - Google Patents
Compuestos macrociclicos y composicion farmaceuticaInfo
- Publication number
- AR065583A1 AR065583A1 ARP080100884A ARP080100884A AR065583A1 AR 065583 A1 AR065583 A1 AR 065583A1 AR P080100884 A ARP080100884 A AR P080100884A AR P080100884 A ARP080100884 A AR P080100884A AR 065583 A1 AR065583 A1 AR 065583A1
- Authority
- AR
- Argentina
- Prior art keywords
- hydrogen atom
- alkyl
- alkenyl
- halogen
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D497/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D497/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D497/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D515/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D515/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D513/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D513/20—Spiro-condensed systems
Abstract
Compuestos con actividad inhibidora de la enzima HSP90 y utiles como agentes anticancerosos o similares, y compuestos que son utiles como intermediarios sintéticos de los mismos y composicion farmacéutica. Reivindicacion 1: Un compuestorepresentado por la formula (1) o una sal del mismo aceptable para su uso farmacéutico, donde X representa CH o N; R1 representa un átomo de hidrogeno, halogeno, un grupo ciano, alquilo C1-6, haloalquilo C1-4, alquenilo C2-6, alquinilo C2-6, alcoxiC1-6, o alquiltio C1-6; R2 representa un átomo de hidrogeno, halogeno, un grupo alquilo C1-6, alquenilo C2-6, o alquinilo C2-6, o R2 y R3 juntos forman un anillo; R3 representa un átomo de hidrogeno, halogeno, un grupo ciano, alquilo C1-6, alqueniloC2-6, alquinilo C2-6, o alcoxi C1-6, o R2 y R3 juntos forman un anillo; R4 representa un átomo de hidrogeno, halogeno, un grupo alquilo C1-6, alquenilo C2-6, o alquinilo C2-6; R5, R6, y R7 representan cada uno independientemente un grupo alquilenoC1-6, alquenileno C2-6, alquinileno C2-6, cicloalquileno C3-10, cicloalquenileno C3-10, arileno C6-12, o anillo monociclico heterocíclico de entre 3 y 12 miembros, cada uno de los cuales puede tener un sustituyente; L1, L2, y L3 representan cada unoindependientemente una union simple, -CONR8-, -NR8CO-, -NR8-, -O-, -SO2NR8-, -NR8SO2-, -COO-, -NR8CONR8'-, -NR8COO-, o -OCONR8-; R8 y R8' representan cada uno independientemente un átomo de hidrogeno o un grupo alquilo C1-6 que puede tener unsustituyente.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007052072 | 2007-03-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR065583A1 true AR065583A1 (es) | 2009-06-17 |
Family
ID=39721348
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP080100884A AR065583A1 (es) | 2007-03-01 | 2008-02-29 | Compuestos macrociclicos y composicion farmaceutica |
Country Status (18)
Country | Link |
---|---|
US (1) | US8362236B2 (es) |
EP (1) | EP2119718B1 (es) |
JP (1) | JP5235859B2 (es) |
KR (1) | KR20090125155A (es) |
CN (1) | CN101675059A (es) |
AR (1) | AR065583A1 (es) |
AT (1) | ATE553107T1 (es) |
AU (1) | AU2008220009A1 (es) |
BR (1) | BRPI0808524A2 (es) |
CA (1) | CA2679126A1 (es) |
CL (1) | CL2008000629A1 (es) |
IL (1) | IL200009A0 (es) |
MX (1) | MX2009008756A (es) |
PE (1) | PE20090110A1 (es) |
RU (1) | RU2009136343A (es) |
TW (1) | TW200904435A (es) |
WO (1) | WO2008105526A1 (es) |
ZA (1) | ZA200905116B (es) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR061185A1 (es) * | 2006-05-26 | 2008-08-13 | Chugai Pharmaceutical Co Ltd | Compuestos heterociclicos como inhibidores de hsp90. composiciones farmaceuticas. |
KR20090125155A (ko) | 2007-03-01 | 2009-12-03 | 추가이 세이야쿠 가부시키가이샤 | 마크로 고리상 화합물 |
AR077405A1 (es) | 2009-07-10 | 2011-08-24 | Sanofi Aventis | Derivados del indol inhibidores de hsp90, composiciones que los contienen y utilizacion de los mismos para el tratamiento del cancer |
FR2949467B1 (fr) | 2009-09-03 | 2011-11-25 | Sanofi Aventis | Nouveaux derives de 5,6,7,8-tetrahydroindolizine inhibiteurs d'hsp90, compositions les contenant et utilisation |
KR101692600B1 (ko) | 2012-03-06 | 2017-01-03 | 화이자 인코포레이티드 | 증식성 질환 치료용 거대환형 유도체 |
US10017481B2 (en) * | 2012-03-17 | 2018-07-10 | Polyphor Ag | Conformationally constrained, fully synthetic macrocyclic compounds |
EP2970334B1 (en) | 2013-03-15 | 2018-05-23 | Biogen MA Inc. | Macrocyclic compounds as irak4 inhibitors for the treatment of inflammatory diseases |
RU2657783C2 (ru) | 2013-09-30 | 2018-06-15 | Тайхо Фармасьютикал Ко., Лтд. | Комбинированная терапия с использованием азабициклосоединения для ракового заболевания |
US11807664B2 (en) | 2017-05-12 | 2023-11-07 | Chugai Seiyaku Kabushiki Kaisha | Method for producing cyclic organic compound |
CN115124550B (zh) * | 2020-10-26 | 2024-04-02 | 山东大学 | 一种特异性热休克蛋白90α亚型抑制剂制备及其应用 |
WO2022089449A1 (zh) * | 2020-10-26 | 2022-05-05 | 山东大学 | 一种特异性热休克蛋白90α亚型抑制剂制备及其应用 |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5170780A (ja) | 1974-12-17 | 1976-06-18 | Nippon Shinyaku Co Ltd | Shinkinabenzoguanidoruino seiho |
AU585761B2 (en) | 1984-03-07 | 1989-06-22 | E.I. Du Pont De Nemours And Company | Herbicidal fluoroethoxy triazines |
JPS60208968A (ja) | 1984-03-07 | 1985-10-21 | イー・アイ・デユポン・デ・ニモアス・アンド・カンパニー | 除草剤性フルオロエトキシピリミジン類及びトリアジン類 |
TW440563B (en) | 1996-05-23 | 2001-06-16 | Hoffmann La Roche | Aryl pyrimidine derivatives and a pharmaceutical composition thereof |
IL128516A0 (en) | 1996-11-01 | 2000-01-31 | Warner Lambert Co | Isoquinolones |
US5968921A (en) | 1997-10-24 | 1999-10-19 | Orgegon Health Sciences University | Compositions and methods for promoting nerve regeneration |
WO1999051223A1 (en) | 1998-04-03 | 1999-10-14 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Benzoquinoid ansamycins for the treatment of cardiac arrest and stroke |
JP2001226358A (ja) | 1999-10-12 | 2001-08-21 | Japan Tobacco Inc | Lpl活性増強剤 |
PL203805B1 (pl) | 2000-02-25 | 2009-11-30 | Hoffmann La Roche | Zastosowanie cyklicznych związków heteroaromatycznych, lek i cykliczne związki heteroaromatyczne |
US6887853B2 (en) | 2000-06-29 | 2005-05-03 | The Trustees Of Boston University | Use of geldanamycin and related compounds for treatment of fibrogenic disorders |
EP1322307B1 (en) | 2000-07-28 | 2011-09-28 | Sloan-Kettering Institute For Cancer Research | Methods for treating cell proliferative disorders and viral infections |
JP2004512381A (ja) | 2000-11-02 | 2004-04-22 | スローン−ケッタリング・インスティテュート・フォー・キャンサー・リサーチ | Hsp90インヒビターの使用により細胞毒性剤の効力を増強させる方法 |
US7439359B2 (en) | 2000-11-02 | 2008-10-21 | Sloan-Kettering Institute For Cancer Research | Small molecule compositions for binding to hsp90 |
EP1440072A4 (en) | 2001-10-30 | 2005-02-02 | Conforma Therapeutic Corp | PURINE ANALOGS HAVING HSP90 INHIBITORY ACTIVITY |
WO2003037346A1 (en) | 2001-10-31 | 2003-05-08 | Cell Therapeutics, Inc. | 6-phenyl-n-phenyl-(1,3,5) -triazine-2,4-diamine derivatives and related compounds with lysophphosphatidic acid acyltransferase beta (lpaat-beta) inhibitory activity for use in the treatment of cancer |
EP1321169A1 (en) | 2001-12-18 | 2003-06-25 | Biofrontera Pharmaceuticals AG | Combination of a serotonin receptor antagonist with a histidine decarboxylase inhibitor as a medicament |
AU2002356301A1 (en) | 2001-12-21 | 2003-07-15 | Cancer Research Technology Ltd. | 3,4-diarylpyrazoles and their use in the therapy of cancer |
ATE433961T1 (de) | 2002-02-08 | 2009-07-15 | Conforma Therapeutics Corp | Ansamycine mit verbesserten pharmakologischen und biologischen eigenschaften |
US7419984B2 (en) | 2002-10-17 | 2008-09-02 | Cell Therapeutics, Inc. | Pyrimidines and uses thereof |
GB0228417D0 (en) | 2002-12-05 | 2003-01-08 | Cancer Rec Tech Ltd | Pyrazole compounds |
CA2537135C (en) | 2003-08-29 | 2013-10-08 | Vernalis (Cambridge) Limited | Pyrimidothiophene compounds |
JP2005225787A (ja) | 2004-02-12 | 2005-08-25 | Nippon Kayaku Co Ltd | Hsp90阻害剤 |
GB0416168D0 (en) | 2004-07-20 | 2004-08-18 | Vernalis Cambridge Ltd | Pyrmidothiophene compounds |
EP2049497A2 (en) | 2005-05-19 | 2009-04-22 | Astex Therapeutics Limited | Pyrimidine derivatives as hsp90 inhibitors |
DE102005022977A1 (de) | 2005-05-19 | 2006-12-07 | Merck Patent Gmbh | Phenylchinazolinderivate |
BRPI0618552B8 (pt) | 2005-11-16 | 2021-05-25 | Cell Therapeutics Inc | compostos derivados de pirimidina ligados ao oxigênio,composição farmacêutica que inclui os ditos compostos,método de síntese dos compostos e usos terapêuticos dos mesmos |
AR061185A1 (es) * | 2006-05-26 | 2008-08-13 | Chugai Pharmaceutical Co Ltd | Compuestos heterociclicos como inhibidores de hsp90. composiciones farmaceuticas. |
KR20090125155A (ko) | 2007-03-01 | 2009-12-03 | 추가이 세이야쿠 가부시키가이샤 | 마크로 고리상 화합물 |
JP2009067729A (ja) | 2007-09-14 | 2009-04-02 | Kyowa Hakko Kirin Co Ltd | Hsp90ファミリー蛋白質阻害剤 |
EP2252595B1 (en) | 2008-02-01 | 2014-03-26 | Takeda Pharmaceutical Company Limited | Oxim derivatives as hsp90 inhibitors |
-
2008
- 2008-02-29 KR KR1020097020448A patent/KR20090125155A/ko not_active Application Discontinuation
- 2008-02-29 MX MX2009008756A patent/MX2009008756A/es not_active Application Discontinuation
- 2008-02-29 TW TW097107103A patent/TW200904435A/zh unknown
- 2008-02-29 AU AU2008220009A patent/AU2008220009A1/en not_active Abandoned
- 2008-02-29 WO PCT/JP2008/053599 patent/WO2008105526A1/ja active Application Filing
- 2008-02-29 RU RU2009136343/04A patent/RU2009136343A/ru unknown
- 2008-02-29 AT AT08721047T patent/ATE553107T1/de active
- 2008-02-29 JP JP2009501315A patent/JP5235859B2/ja not_active Expired - Fee Related
- 2008-02-29 CA CA002679126A patent/CA2679126A1/en not_active Abandoned
- 2008-02-29 CN CN200880014171A patent/CN101675059A/zh not_active Withdrawn
- 2008-02-29 AR ARP080100884A patent/AR065583A1/es unknown
- 2008-02-29 BR BRPI0808524-2A2A patent/BRPI0808524A2/pt not_active IP Right Cessation
- 2008-02-29 EP EP08721047A patent/EP2119718B1/en not_active Not-in-force
- 2008-02-29 PE PE2008000409A patent/PE20090110A1/es not_active Application Discontinuation
- 2008-02-29 US US12/529,222 patent/US8362236B2/en not_active Expired - Fee Related
- 2008-02-29 CL CL200800629A patent/CL2008000629A1/es unknown
-
2009
- 2009-07-22 ZA ZA200905116A patent/ZA200905116B/xx unknown
- 2009-07-22 IL IL200009A patent/IL200009A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
CL2008000629A1 (es) | 2008-08-29 |
MX2009008756A (es) | 2009-08-27 |
US20100056510A1 (en) | 2010-03-04 |
EP2119718A4 (en) | 2010-12-15 |
WO2008105526A1 (ja) | 2008-09-04 |
PE20090110A1 (es) | 2009-04-04 |
KR20090125155A (ko) | 2009-12-03 |
EP2119718A1 (en) | 2009-11-18 |
JPWO2008105526A1 (ja) | 2010-06-03 |
BRPI0808524A2 (pt) | 2014-11-11 |
EP2119718B1 (en) | 2012-04-11 |
RU2009136343A (ru) | 2011-04-10 |
US8362236B2 (en) | 2013-01-29 |
AU2008220009A1 (en) | 2008-09-04 |
TW200904435A (en) | 2009-02-01 |
IL200009A0 (en) | 2010-04-15 |
JP5235859B2 (ja) | 2013-07-10 |
ATE553107T1 (de) | 2012-04-15 |
CA2679126A1 (en) | 2008-09-04 |
ZA200905116B (en) | 2010-07-28 |
CN101675059A (zh) | 2010-03-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR065583A1 (es) | Compuestos macrociclicos y composicion farmaceutica | |
AR054799A1 (es) | Derivados de oxindol | |
AR072952A1 (es) | Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso | |
AR088829A1 (es) | DERIVADOS DE CICLOHEXILAMINA QUE TIENEN ACTIVIDAD COMO AGONISTAS ADRENERGICOS b2 Y COMO ANTAGONISTAS MUSCARINICOS M3 | |
AR070558A1 (es) | Derivados de 7-fenil-7h-pirrolo-[2,3d]-pirimidin-2-il-amino,proceso para prepararlos, composiciones farmaceuticas que los comprenden y uso de los mismos para el tratamiento de enfermedades dependientes de tirosinquinasas,tales como enfermedades proliferativas. | |
AR074435A1 (es) | Derivados de 1,3-benzotiazol, medicamentos que los contienen y uso de los mismos en el tratamiento del cancer. | |
AR080057A1 (es) | Piridinas disustituidas como anticancerigenos | |
AR057131A1 (es) | Derivados de purina como inmunomodulador | |
ES2530943T3 (es) | Derivados de la cromenona con actividad antitumoral | |
AR072576A1 (es) | Metodo para la represion de malezas en un cesped | |
AR072906A1 (es) | Nucleosidos modificados utiles como antivirales | |
EA201690019A1 (ru) | Производное аминотриазина и содержащая его фармацевтическая композиция | |
AR058885A1 (es) | Compuestos de piperidina 3,5-sustituidos | |
AR057688A1 (es) | CARBOXAMIDAS HETEROCíCLICAS Y SU USO EN COMPOSICIONES FUNGICIDAS. | |
ECSP055974A (es) | Síntesis de cloruros de 4 amino-2-butenoil y su uso en la preparación de 3-ciano quinolinas | |
AR055635A1 (es) | Uso de sulfonanilidas como herbicidas | |
AR065280A1 (es) | Agentes antiparasitarios | |
AR082153A1 (es) | N-sulfonilbenzamidas utiles como inhibidor del canal de sodio | |
CO6140033A2 (es) | Amino-imidazoles y su uso como medicamento para tratar discapacidad coognotiva enfermedad de alzheimer neurodegeneracion y demencia | |
AR060050A1 (es) | Compuestos moduladores del receptor de s1p y uso de los mismos | |
AR058554A1 (es) | Compuestos heterociclicos nitrogenados de 6 miembros sustituidos, metodos para su preparacion, composiciones farmaceuticas que los contienen y su uso en el tratamiento de enfermedades mediadas por mglur5. | |
CO6220949A2 (es) | Derivados pirazolicos como inhibidores de la 11 beta -hsd1 | |
AR078536A1 (es) | Derivados de pirazol como ligandos del receptor de estrogeno | |
AR077977A1 (es) | Compuestos y composiciones como inhibidores de cinasa de proteina | |
PE20142081A1 (es) | Inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas y metodo de uso de los mismos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |